VarmX raises €32M in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
08/07/2020 Press release VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVERSAL AGENT FOR THE TREATMENT AND PREVENTION OF SEVERE BLEEDING IN PATIENTS ON ORAL ANTICOAGULANTS. • Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures , LSP, and existing investors BioGeneration Ventures and InnovationQuarter • Proceeds to be…